Modeling APC, a gene whose role in lung cancer is not as well understood, revealed that APC loss also
drives tumor progression.
Not exact matches
Wistar scientists have previously shown that age - related changes in the
tumor microenvironment — or the surrounding area where
tumor cells crosstalk with normal and immune cells — can
drive melanoma
progression and therapy resistance.
CSCs are thought to
drive tumor recurrence,
progression, metastasis and drug resistance.
Anna Huttenlocher, University of Wisconsin, USA Neutrophils in the
Tumor Microenvironment Neutrophils, Wounds, and Cancer
Progression Stefan Kaufmann, Max Planck Institute, Germany Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells Kathryn Moore, New York University, USA MicroRNA -33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis Lalita Ramakrishnan, University of Cambridge, UK Myeloid Growth Factors Promote Resistance to Mycobacterial Infection by Curtailing Granuloma Necrosis through Macrophage Replenishment Beth Stevens, Harvard University, USA Microglia: Dynamic Mediators of Synapse Development and Plasticity Do glia
drive synaptic and cognitive impairment in disease?
Although a large number of genetic alterations that
drive the development and
progression of many types of cancer have been identified through large - scale research studies, some
tumor types have not been deeply characterized.
The mission of our lab is to improve therapy for patients with brain
tumors by elucidating the molecular mechanisms
driving cancer initiation and
progression, and in doing so, promote rigorous science and train the next generation of scientists.